Clinical CDK4/6 inhibitors induce selective and immediate dissociation of p21 from cyclin D-CDK4 to inhibit CDK2

Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future

(2020) Laura M Spring et al.   LANCET

Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition

(2020) Mónica Álvarez-Fernández et al.   CANCER CELL

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

(2020) Seth A. Wander et al.   Cancer Discovery

Altered G1 signaling order and commitment point in cells proliferating without CDK4/6 activity

(2020) Chad Liu et al.   Nature Communications

MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance

(2019) Liam Cornell et al.   Cell Reports

Signalling involving MET and FAK supports cell division independent of the activity of the cell cycle-regulating CDK4/6 kinases

(2019) Chi Zhang et al.   ONCOGENE

Biomarker Analyses of Response to Cyclin Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women With Treatment-Naïve Metastatic Breast Cancer

(2019) Richard S. Finn et al.   CLINICAL CANCER RESEARCH

Transient Hysteresis in CDK4/6 Activity Underlies Passage of the Restriction Point in G1

(2019) Mingyu Chung et al.   MOLECULAR CELL

Putting the brakes on the cell cycle: mechanisms of cellular growth arrest

(2019) Lindsey R Pack et al.   CURRENT OPINION IN CELL BIOLOGY

p27 allosterically activates cyclin-dependent kinase 4 and antagonizes palbociclib inhibition

(2019) Keelan Z. Guiley et al.   SCIENCE

A Precise Cdk Activity Threshold Determines Passage through the Restriction Point

(2018) Clayton Schwarz et al.   MOLECULAR CELL

Stochastic Endogenous Replication Stress Causes ATR-Triggered Fluctuations in CDK2 Activity that Dynamically Adjust Global DNA Synthesis Rates

(2018) Leighton H. Daigh et al.   Cell Systems

Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway

(2018) Zhiqiang Li et al.   CANCER CELL

Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: A review

(2018) Kamal Pandey et al.   INTERNATIONAL JOURNAL OF CANCER

DNA damage during S-phase mediates the proliferation-quiescence decision in the subsequent G1 via p21 expression

(2017) Alexis R. Barr et al.   Nature Communications

Differential Regulation of G1 CDK Complexes by the Hsp90-Cdc37 Chaperone System

(2017) Stephen T. Hallett et al.   Cell Reports

Endogenous Replication Stress in Mother Cells Leads to Quiescence of Daughter Cells

(2017) Mansi Arora et al.   Cell Reports

A map of protein dynamics during cell-cycle progression and cell-cycle exit

(2017) Sara Gookin et al.   PLOS BIOLOGY

Early Adaptation and Acquired Resistance to CDK4/6 Inhibition in Estrogen Receptor–Positive Breast Cancer

(2016) Maria Teresa Herrera-Abreu et al.   CANCER RESEARCH

Irreversible APC Cdh1 Inactivation Underlies the Point of No Return for Cell-Cycle Entry

(2016) Steven D. Cappell et al.   CELL

Treating cancer with selective CDK4/6 inhibitors

(2016) Ben O'Leary et al.   Nature Reviews Clinical Oncology

Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence

(2016) C Yang et al.   ONCOGENE

Targeting CDK6 in cancer: State of the art and new insights

(2015) Solomon Tadesse et al.   CELL CYCLE

Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment

(2015) T. VanArsdale et al.   CLINICAL CANCER RESEARCH

Sequential replication-coupled destruction at G1/S ensures genome stability

(2015) Kate E. Coleman et al.   GENES & DEVELOPMENT

Using ancient protein kinases to unravel a modern cancer drug's mechanism

(2015) C. Wilson et al.   SCIENCE

Cyclin E1 and RTK/RAS signaling drive CDK inhibitor resistance via activation of E2F and ETS

(2015) Barbie Taylor-Harding et al.   Oncotarget

CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer

(2015) Jorge Franco et al.   Oncotarget

Exploitation of Latent Allostery Enables the Evolution of New Modes of MAP Kinase Regulation

(2013) Scott M. Coyle et al.   CELL

The Proliferation-Quiescence Decision Is Controlled by a Bifurcation in CDK2 Activity at Mitotic Exit

(2013) Sabrina L. Spencer et al.   CELL

A Cdk7-Cdk4 T-Loop Phosphorylation Cascade Promotes G1 Progression

(2013) Miriam Merzel Schachter et al.   MOLECULAR CELL

Quantitative analysis of cell cycle phase durations and PC12 differentiation using fluorescent biosensors

(2011) Angela T. Hahn et al.   CELL CYCLE

Incomplete Folding upon Binding Mediates Cdk4/Cyclin D Complex Activation by Tyrosine Phosphorylation of Inhibitor p27 Protein

(2011) Li Ou et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

A pharmacological cocktail for arresting actin dynamics in living cells

(2011) Grace E. Peng et al.   MOLECULAR BIOLOGY OF THE CELL

A Guide to Simple and Informative Binding Assays

(2010) Thomas D. Pollard   MOLECULAR BIOLOGY OF THE CELL

Crystal structure of human CDK4 in complex with a D-type cyclin

(2009) P. J. Day et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Visualizing Spatiotemporal Dynamics of Multicellular Cell-Cycle Progression

(2008) Asako Sakaue-Sawano et al.   CELL

CDK Inhibitors: Cell Cycle Regulators and Beyond

(2008) Arnaud Besson et al.   DEVELOPMENTAL CELL

PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex

(2008) T. Abbas et al.   GENES & DEVELOPMENT

The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing

(2008) Y. Kim et al.   GENES & DEVELOPMENT

CDK Inhibitor p21 Is Degraded by a Proliferating Cell Nuclear Antigen-coupled Cul4-DDB1Cdt2Pathway during S Phase and after UV Irradiation

(2008) Hideo Nishitani et al.   JOURNAL OF BIOLOGICAL CHEMISTRY